A Phase 1 interventional study of Sulthiame in Renal Impairment, sponsored by Shionogi. Not yet recruiting at 2 sites in United States. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-05.
Sponsored by Shionogi · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 554 studies in Renal Insufficiency with a site in United States — 41 open to participants now, 57 under way, 3 of them phase 3. Renal Insufficiency · United States.
Among the 554 studies in Renal Insufficiency with a site in United States, this one is the 247th largest by planned enrollment of the 469 interventional ones that give a count, is one of 16 that started in 2026, is one of 233 in phase 1, reaches primary completion later than 14 of the 56 other live ones, and was the 550th registered.
1,414 studies on the registry are indexed under Renal Insufficiency; 147 are open to participants now.
Browse Renal Insufficiency studies →41 of the 554 studies in Renal Insufficiency with a site in United States are open now. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in United States
Ages 18–80 · Healthy volunteers
Sanofi · Sites in United States
Ages 18–75 · Healthy volunteers
Hoffmann-La Roche · Sites in United States
Ages 18–85 · Healthy volunteers
Merck Sharp & Dohme LLC · Sites in United States
Ages 18–80 · Healthy volunteers
Kailera · Sites in United States
Ages 18–85 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 93 Renal Insufficiency studies recruiting now, 49 (53%) set no upper age limit and 19 (20%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
554 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 248 · Phase 2 71 · Phase 3 53 · Phase 4 44
First in 1990; this study’s year is marked. 16 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 40 across 1,062 interventional studies indexed under Renal Insufficiency.
Median enrollment 32 across the 469 interventional studies, 182 across the 82 observational. Of the 465 that completed or were terminated, 169 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
335 of 554 have an industry lead sponsor. The 10 most frequent:
Shionogi is the lead sponsor of 105 studies on the registry; 10 are open to participants now.
Of its 39 completed or terminated interventional studies of FDA-regulated products, 21 (54%) have results posted.
Shionogi has 5 studies filed under Renal Insufficiency — fewer than ten, so there is no comparison to draw.
23 of the studies in Renal Insufficiency with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04020055Phase 3Amicus TherapeuticsA Study to Evaluate Migalastat in Fabry Subjects With Amenable GLA Variant and Renal Disease | 2026-12-31 |
| NCT07341516Paris Translational Research Center for Organ TransplantationWorldwide Assessment of Deceased Donor Kidney Utilization | 2026-11 |
| NCT04605679Loma Linda UniversityHepatitis C Virus (HCV) Positive Kidney Grafts in HCV Negative Recipients | 2026-12 |
| NCT07857837ShionogiStudy of Sulthiame (S-054502) in Participants With Renal Impairment and Matched Healthy Controls | 2026-12-04 |
| NCT03099434Johns Hopkins UniversityExpanding Live Donor Kidney Transplantation Through Advocacy Training and Social Media | 2026-12-07 |
Add all 23 to your calendar (.ics) → With an account.
Among the 554 studies in Renal Insufficiency with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the pharmacokinetics (PK), safety, and tolerability of sulthiame in participants with mild and moderate renal impairment compared to those in healthy participants with normal renal function.
Key Inclusion Criteria:
All Participants:
Participants With Renal Impairment (Groups A and B):
Participants who have mild and moderate renal impairment based on estimated (eGFR) calculated using the 2021 Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine formula and the participant's body surface area (BSA) at the screening visit (Day -28 to -2).
Healthy Participants With Normal Renal Function (Group C):
Key Exclusion Criteria:
All Participants:
Participants With Renal Impairment (Groups A and B):
Healthy Participants With Normal Renal Function (Group C):
Note: Other protocol-defined inclusion and exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with mild renal impairment will receive a single dose of sulthiame in the fasted state on Day 1.
Drug: Sulthiame
Participants with moderate renal impairment will receive a single dose of sulthiame in the fasted state on Day 1.
Drug: Sulthiame
Healthy participants with normal renal function will receive a single dose of sulthiame in the fasted state on Day 1.
Drug: Sulthiame
Tablet for oral administration
Also known as: S-054502
Maximum Observed Plasma Concentration (Cmax) of Sulthiame
Time frame: 0 (predose) up to 168 hours postdose (Day 1 up to Day 8)
Time to Reach Cmax (Tmax) of Sulthiame
Time frame: 0 (predose) up to 168 hours postdose (Day 1 up to Day 8)
Area Under the Plasma Concentration-time Curve Extrapolated From Time 0 to the time of the Last Quantifiable Concentration After Dosing (AUC0-last) of Sulthiame
Time frame: 0 (predose) up to 168 hours postdose (Day 1 up to Day 8)
Cmax of Sulthiame Metabolite
Time frame: 0 (predose) up to 168 hours postdose (Day 1 up to Day 8)
Tmax of Sulthiame Metabolite
Time frame: 0 (predose) up to 168 hours postdose (Day 1 up to Day 8)
AUC0-last of Sulthiame Metabolite
Time frame: 0 (predose) up to 168 hours postdose (Day 1 up to Day 8)
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
Time frame: Day 1 up to Day 15
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Sep 2026; primary completion for Dec 2026, 2 months later.
Of 213 industry-sponsored phase 1 interventional studies under Renal Insufficiency, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's planned 2 months is below that.
Counting every sponsor, half of 231 studies reached it within 8 months; a quarter within 5 and three quarters within 16.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sulthiame